Pathology Funded Studentships
The Department of Pathology has an excellent reputation in pure biological and biomedical research and is offering fully funded* studentships from October 2027 to work with one of the Research Group Leaders in this large and vibrant Department.
All applications should be made online via the University’s Applicant Portal for a PhD in Pathology (BLPA22). A completed application must be submitted by the closing date below. An application is only complete when all supporting documents, including the 2 academic references, are submitted.
It is the applicant’s responsibility to ensure their referees submit their references before the closing date of the studentship.
The studentships are available to students who qualify for UK HOME FEES ONLY
Please check for eligibility details using this website: https://www.postgraduate.study.cam.ac.uk/finance/fees/what-my-fee-status
*Funding will cover the student’s stipend at the current Research Council rate and Home University Fees. The studentship will be funded for 4 years from October 2027.
Applicants should hold (or expect to obtain) the equivalent of a UK upper 2.1 or higher in an undergraduate honours or Masters degree in a relevant subject. The studentship is open to those eligible for the Home rate of University fees. Additionally, the Department requires that by the time of interview all potential students must have fulfilled the language requirements for admission.
(http://www.graduate.study.cam.ac.uk/courses/directory/blpapdpth/requirements)
Please also explain your motivation why you wish to pursue a PhD in this area, outline your research interests and background, and describe the qualities and experience you will bring to the role.
Applications from ineligible candidates will not be considered. Further information about the course can be found here.
Closing date: 2nd December 2026
Studentship 1:
Katerina Artavanis-Tsakonas
Project Title: Turning the Malaria Parasite’s Protein Degradation Machinery Against It - Professor Katerina Artavanis-Tsakonas, co-supervised with Laura Itzhaki (Department of Pharmacology)
Can we turn the malaria parasite’s own protein-degradation machinery against it?
Malaria remains one of the world’s most important infectious diseases, and the continuing emergence of drug resistance creates an urgent need for new interventions. Most antimalarial drugs work by blocking the activity of an essential protein or pathway. This project will explore a fundamentally different approach that harnesses the parasite’s own machinery to destroy essential proteins rather than simply inhibiting them.
By harnessing the ubiquitin-proteasome system, the cellular machinery responsible for recognising and removing unwanted proteins, targeted protein degradation is transforming drug discovery, particularly in cancer. Its potential in malaria, however, remains largely unexplored. Our lab has spent over 15 years investigating the Plasmodium ubiquitin system and has uncovered a surprisingly complex pathway containing proteins and mechanisms that differ substantially from those found in human cells. These differences provide an exciting opportunity both to discover fundamental parasite biology and to identify vulnerabilities that could ultimately be exploited therapeutically.
This project will investigate how parasite proteins can be selectively directed for degradation, initially developing and testing proof-of-principle systems before applying them to biologically important parasite targets. The project brings together molecular parasitology, genetics, biochemistry, chemical biology and proteomics, giving the student the opportunity to work across disciplines and develop new experimental approaches.
The goal is both to create powerful tools for asking previously inaccessible questions about parasite biology and to explore whether targeted protein degradation could provide an entirely new strategy for antimalarial development.
Studentship 2:
Matt Murray
Project title: Exploring functional effects of dysregulated microRNA-mediated cellular pathways in malignant germ cell tumours – Dr Matthew Murray
Although most patients with malignant germ cell tumours (GCTs) have a good prognosis with platinum treatment, some still experience inferior outcomes, either in terms of survival (testicular germ cell malignancy remains a leading cause of death in young men) or quality-of-life (through multiple long-term late-effects of treatment including cardiovascular disease and second malignancy). Improved understanding of the molecular pathogenesis of malignant GCTs is an important step towards developing novel therapeutic agents with favourable toxicity profiles, which may improve survival for patients with high-risk disease and reduce toxicity for low-risk patients.
Our team has demonstrated that malignant GCTs are characterised by specific microRNA (miRNA) dysregulation across the spectrum of clinical disease observed (patient age, tumour site and subtype) [1-3], which we aim to exploit to address this unmet clinical need.
Our global miRNA profiling and functional studies to date have identified key oncogenic and tumour-suppressor candidate miRNAs, which warrant further study. We have already targeted and manipulated over-expressed miR-371/373 and miR-302/367 miRNAs to demonstrate a phenotypic and genotypic effect on malignant GCT cells [1] and the tumour microenvironment [2]. Conversely, we have replenished the downregulated let-7 miRNAs and coregulated miR-100-5p/125b-5p [3] in malignant GCT cell lines with phenotypic and genotypic effects.
This project will extend those observations in engineered inducible malignant GCT cell lines in vitro which can, e.g., express miR-100-5p/miR-125b-5p upon doxycycline treatment. Combination treatment using miRNA replenishment/targeting approaches with cisplatin will also be investigated, and novel agents targeting identified affected cellular pathways, prior to in vivo studies.
This project will utilise established in vitro and in vivo techniques in our laboratory, including: cell culture; cell model systems; cell proliferation and other readout assays; RNA extraction (mRNA and miRNA) and quantification using sequencing/PCR, protein extraction and western blot analysis and quantification, murine in vivo studies as indicated; data analysis.
Studentship 3:
Brian Ferguson
Project title: Comparative innate immune sensing of zoonotic viruses – Professor Brian Ferguson
Cross-species transmission is a major driver of emerging viral diseases, yet the molecular factors that determine the severity of disease in a new host remain poorly understood. This PhD project will investigate how pattern recognition receptor (PRR) signalling shapes cross-species host/virus interactions, with a particular focus on viruses that infect both mammalian and avian hosts.
The project will examine how differences in nucleic acid sensing PRRs drives differential outcomes to infection. We will analyse how pathogen sensing and downstream signalling pathways influence the outcome of infection across species. In parallel, there will be a focus on understanding how viruses evade or manipulate innate immune responses, and whether viral immune-evasion mechanisms have different effects depending on the host species and its specific immune architecture.
Using comparative virology and immunology approaches, with techniques including proteomics, RNAseq, flow cytometry and molecular virology, we will investigate host and viral determinants of infection, including PRR activation, downstream inflammatory and antiviral signalling, and viral antagonism of these pathways. Comparative studies across mammalian and avian systems will help identify conserved versus species-specific mechanisms of innate immune recognition and viral immune evasion.
The overall aim is to understand how variation in host PRR signalling and viral immune evasion strategies contributes to host range, viral adaptation and successful cross-species transmission. The findings could provide new mechanistic insights into the factors that determine zoonotic potential and help inform approaches for predicting and mitigating the emergence of novel viral pathogens.
Studentship 4:
Colin Crump
Project Title: Investigating mechanisms of cell-to-cell spread of persistent viruses – Professor Colin Crump
Herpesviruses and polyomaviruses are examples of highly successful viruses that can establish life-long infections with periodic shedding of infectious virus enabling transmission to new host. Generally, these viruses cause little or no disease in most of their hosts, but can cause severe disease in some, particularly those with weekend immune systems. These viruses can also be important risk factors of disease in aging populations.
Viruses that infect their hosts long term will have evolved various strategies to maintain reservoirs of infection in the face of active immunity, balancing the need to replicate sufficiently to spread to new cells without stimulating an aggressive anti-viral immune response that could clear the infection. One way to achieve this is to promote mechanisms of cell-to-cell spread that are rapid, efficient and minimise the risks of detection.
This project will investigate the molecular mechanisms involved in the cell-to-cell spread of herpes simplex virus-1 (HSV-1) and BK polyomavirus (BKPyV), human viruses that infect most of the adult population worldwide. A combination of infection studies, cell biology, biochemistry and advanced microscopy imaging approaches will be used to understand how these viruses spread from one cell to another using 2D and 3D cell culture models. The research will make use of a large collection of recombinant viruses lacking different viral gene functions, as well as extensive datasets already generated showing how these viruses modulate the cellular proteome, the different compartments of the secretory pathway, and the cell surface of infected cells.